A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,500 shares of RLAY stock, worth $6,510. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,500
Previous 1,700 11.76%
Holding current value
$6,510
Previous $11,000 9.09%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.23 - $9.51 $10.9 Million - $16.6 Million
1,746,035 Added 150.09%
2,909,371 $20.6 Million
Q2 2024

Aug 14, 2024

BUY
$5.9 - $8.02 $5.46 Million - $7.43 Million
926,136 Added 390.45%
1,163,336 $7.58 Million
Q1 2024

May 15, 2024

SELL
$7.5 - $12.07 $2.7 Million - $4.35 Million
-360,394 Reduced 60.31%
237,200 $1.97 Million
Q4 2023

Feb 14, 2024

SELL
$6.01 - $11.48 $6.52 Million - $12.5 Million
-1,085,255 Reduced 64.49%
597,594 $6.58 Million
Q3 2023

Nov 14, 2023

BUY
$8.24 - $12.97 $11.3 Million - $17.8 Million
1,374,834 Added 446.35%
1,682,849 $14.2 Million
Q2 2023

Aug 14, 2023

BUY
$9.99 - $18.27 $2.87 Million - $5.25 Million
287,296 Added 1386.63%
308,015 $3.87 Million
Q1 2023

May 15, 2023

SELL
$15.0 - $22.76 $1.7 Million - $2.59 Million
-113,641 Reduced 84.58%
20,719 $341,000
Q4 2022

Feb 14, 2023

SELL
$14.16 - $24.02 $1.68 Million - $2.84 Million
-118,380 Reduced 46.84%
134,360 $2.01 Million
Q3 2022

Nov 14, 2022

BUY
$18.07 - $31.37 $4.04 Million - $7.02 Million
223,821 Added 773.96%
252,740 $5.65 Million
Q2 2022

Aug 15, 2022

SELL
$13.31 - $34.88 $947,339 - $2.48 Million
-71,175 Reduced 71.11%
28,919 $484,000
Q1 2022

May 16, 2022

SELL
$20.26 - $32.36 $3.09 Million - $4.94 Million
-152,665 Reduced 60.4%
100,094 $3 Million
Q4 2021

Feb 14, 2022

BUY
$26.0 - $37.03 $1.73 Million - $2.46 Million
66,512 Added 35.71%
252,759 $7.76 Million
Q3 2021

Nov 15, 2021

BUY
$29.75 - $37.99 $1.76 Million - $2.24 Million
58,996 Added 46.36%
186,247 $5.87 Million
Q2 2021

Aug 16, 2021

BUY
$27.5 - $38.19 $13,145 - $18,254
478 Added 0.38%
127,251 $4.66 Million
Q1 2021

May 17, 2021

BUY
$32.52 - $61.53 $2.07 Million - $3.92 Million
63,776 Added 101.24%
126,773 $4.38 Million
Q4 2020

Feb 16, 2021

BUY
$35.51 - $54.03 $316,181 - $481,083
8,904 Added 16.46%
62,997 $2.62 Million
Q3 2020

Nov 16, 2020

BUY
$32.81 - $45.1 $1.77 Million - $2.44 Million
54,093 New
54,093 $2.3 Million

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $522M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.